FDA DEVICE FACTS
LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus
DiaSorin, Inc.
Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。
Indications for use
LIAISON Biotrin Parvovirus B19 IgG Plus The LIAISON Biotrin Parvovirus B19 IgG Plus, a chemiluminescent immunoassay (CLIA), is intended for the qualitative detection of IgG antibodies to B19 virus (B19V, previously known as human parvovirus B19) in human serum, lithium heparin, dipotassium EDTA (K 2-EDTA), and sodium citrated plasma. The test may be used for testing women of childbearing age where there is a suspicion of exposure to human B19V. The test may also be used for all patients as an aid in the diagnosis of fifth disease (erythema infectiosum). The test must be performed on the LIAISON XL Analyzer. LIAISON Biotrin Control Parvovirus B19 IgG Plus The LIAISON Biotrin Control Parvovirus B19 IgG Plus (negative and positive) is intended for use as assayed quality control samples to monitor the performance and reliability of LIAISON Biotrin Parvovirus B19 IgG Plus assay. The performance characteristics of LIAISON Biotrin Control Parvovirus B19 IgG Plus have not been established for any other assays or instrument platforms different from the automated LIAISON XL Analyzer.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。